NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health...(ized controlled clinical trials leading ...)

Date:10/15/2008

ized, controlled clinical trials, leading to their approval by the Food and Drug Administration (FDA) and wide dissemination to patients. These have included the anticonvulsants valproate (Depakote) and lamotrigine (Lamictal), and the atypical antipsychotic quetiapine (Seroquel). These agents have vastly enlarged our treatment armamentarium and provided new options for patients with bipolar disorder, making it possible for many who have not responded well to other approaches to achieve substantial improvement or remission."

Mark S. George, M.D., the second recipient of the Falcone Prize, is Distinguished Professor of Psychiatry at the Medical University of South Carolina, where he also directs the Center for Advanced Imaging Research and the Brain Stimulation Laboratory. He is one of the world's leading experts in the use of brain imaging and stimulation to understand depression and to devise new antidepressant treatments. In early research at the National Institute of Mental Health, Dr. George was one of the first scientists to expand the study of brain imaging technology for psychiatric disorders. He discovered specific brain changes during normal emotion, and began exploring brain changes in depression and mania. This led to his pioneering use of a noninvasive brain stimulation method, transcranial magnetic stimulation (TMS), to probe neuronal circuits regulating mood, and to clinical trials of TMS in patients with treatment-resistant depression. This seminal work resulted in recent approval of TMS by the FDA for use within the United States.

About Dr. George's work, Dr. Post, chair of the prize selection committee wrote: "Dr. George is one of the true young pioneers of modern psychiatry. He has made seminal contributions to the development of new, nonconvulsive physiological interventions --rTMS (repeated transcranial magnetic stimulation) and VNS (vagus nerve stimulation) -- for the treatment of refractory unipolar and bipolar depression. He
'/>"/>

Contact: Kristen Simone ksimone@narsad.org 516-829-0091 NARSAD, The Mental Health Research Association Source:Eurekalert

1 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology news :

1. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
2. At Boston symposium, NARSAD researchers report on genes and family traits
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. LaserCard Corporation Announces Expansion of Middle East Project
5. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
6. Balzan Foundation announces 2007 winners
7. The American Society of Plant Biologists announces 2007 awards
8. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
9. NIST announces 56 new awards for innovative technology research and development
10. Titanium Group Announces Contract With Haitong Securities
11. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results